Table 2. The 2- and 5-year cumulative AML incidences with mortality as the competing risk and with left truncation, and the 2- and 5-year OS probabilities with left truncation.
| Cumulative AML incidences, % (95% CI) | Lenalidomide-treated | Untreated |
|---|---|---|
| Overall population | (n=295) | (n=125) |
| Two-year | 6.9 (3.3–13.9) | 12.1 (7.0–20.3) |
| Five-year | 22.8 (17.1–30.3) | 19.9 (12.9–30.0) |
| Patients with WHO-defined isolated del(5q)a | (n=160) | (n=85) |
| Two-year | 6.6 (2.5–16.7) | 7.4 (3.1–16.9) |
| Five-year | 18.1 (11.3–28.1) | 16.9 (9.4–29.4) |
|
OS probabilities, % (95% CI) |
Lenalidomide-treated |
Untreated |
| Overall population | (n=295) | (n=125) |
| Two-year | 89.9 (84.1–96.0) | 74.4 (66.1–83.7) |
| Five-year | 53.7 (46.6–61.9) | 40.5 (30.9–53.1) |
| Patients with WHO-defined isolated del(5q)a | (n=160) | (n=85) |
| Two-year | 93.5 (87.5–99.9) | 76.1 (66.4–87.1) |
| Five-year | 60.2 (51.1–71.0) | 44.4 (32.8–60.3) |
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; OS, overall survival; WHO, World Health Organization.
a
Defined as patients who had isolated del(5q) and <5% bone marrow blasts.